ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria; and ALK 014, a biologic for food allergies. It also provides GRAZAX/GRASTEK, a tablet for grass pollen allergy; ACARIZAX, ODACTRA, and MITICURE/SENSIMUNE, which are tablets for house dust mite allergies; ITULAZAX/ITULATEK, a tablet for tree pollen allergy; RAGWITEK/RAGWIZAX, a tablet for ragweed pollen allergy; and CEDARCURE, a tablet for Japanese cedar pollen allergy. In addition, the company offers consumer healthcare solutions, such as klarify.me, a digital patient engagement platform to help people manage their allergies. Further, it provides allergen extracts for use in the diagnosis of specific allergies, such as skin prick and blood test; and emergency medicine treatment, such as adrenaline autoinjectors, an intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. for the development of GRAZAX and CEDARCURE; and Dr. Reddy's Laboratories for the development of Sensimune. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.…
ALK presents new data at FAAM-EUROBAT-ISMA 2026: Data from a comparative study using adrenaline trainer devices suggests EURneffy® nasal adrenaline spray is more suitable for public places than an adrenaline auto-injector
ALK-Abelló (CPH: ALK-B) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2,795 employees.
The shares were at 239.20 DKK on 20 November 2026, up 4.7% over 52 weeks. Its 52-week range is 191.80 DKK to 271.40 DKK: the price is 11.9% below the high and 24.7% above the low.
At a market capitalisation of 53.00B DKK, it trades at 38.0 times trailing earnings and 32.1 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.1, a premium of 15% for ALK-B. It pays a dividend yielding 0.65% (it pays out 25% of its earnings), against a median of 0.95% among the dividend payers in that peer group.
ALK-Abelló reports return on equity of 18.6%, an operating margin of 26.6% and revenue up 15.3% year over year.
It holds more cash than debt, a net cash position of 1.53B DKK. Its Piotroski F-score is 9 out of 9, a strong reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 289.67 DKK is 21.1% above the current price. The next earnings report is expected on 9 February 2027.